Pancreatic Stone Protein (PSP) Assay
Early Detection and Risk Stratification of Sepsis
CommercialActive
Key Facts
Indication
Early Detection and Risk Stratification of Sepsis
Phase
Commercial
Status
Active
Company
About Abionic
Abionic is a commercial-stage diagnostics company with a proprietary platform for rapid, near-patient testing. Its core product combines the abioSCOPE® benchtop analyzer with a disposable cartridge to measure the Pancreatic Stone Protein (PSP) biomarker, enabling sepsis detection up to 72 hours earlier than standard clinical recognition. The solution targets hospital emergency departments, ICUs, and wards to accelerate sepsis bundle activation and improve patient outcomes. The company is actively generating clinical evidence to support the adoption of PSP across various patient populations and hospital settings.
View full company profile